First, the clinical characteristics of soft tissue tumors are lack of specificity. Most of the patients consult the doctor because of lumps, with or without symptoms such as pain and dysfunction. Clinical considerations: 99% of benign soft tissue tumors are located in superficial tissues, and about 95% of benign tumors have a diameter less than 125 px. When the diameter of the soft tissue mass in the limb is greater than 125 px, and it is located in the deep layer of deep fascia and in the proximal end of the limb, the possibility of malignant tumors should be suspected. Imaging examination plays an important role in the diagnosis of soft tissue sarcoma, especially MRI examination is especially important to provide evidence for comprehensive diagnosis of tumor; the basis for choosing biopsy route and sampling site; the relationship between tumor and its reaction area and surrounding tissues to carry out the development of surgical plan for tumor surgery. Secondly, preoperative biopsy is also getting more and more attention to provide the basis for the final treatment of soft tissue sarcoma. And nowadays, many hospitals hastily carry out resection of soft tissue tumors without biopsy, resulting in many irreparable clinical losses. In fact, it should be kept in mind that biopsy of soft tissue tumors, which is very important, is the principle of diagnosis and treatment of soft group tumors. Another noteworthy phenomenon is the hasty excisional biopsy, which causes difficulties in re-expanding the resection. In fact, only those cases in which the tumor is located in the superficial layer, the diameter is less than 125px, the possibility of benign tumor is high in clinical imaging, and once the tumor is malignant after resection, it can still be performed to expand the resection in order to reach the boundary of wide resection before performing excisional biopsy. Third, there are many treatment methods for soft tissue sarcoma, at present, surgical wide excision of tumor is still the most important treatment means for soft tissue sarcoma. The key of surgery is to grasp the surgical boundary. However, to achieve wide resection in clinical treatment is dependent on the expertise of the treating physicians in bone and soft tissue tumors, their judgment of the scope of the tumor and its surrounding reaction area in the imaging data, as well as their rich clinical experience. Limb-sparing surgery is increasingly widely used in the treatment of limb soft tissue sarcoma. Fourth, the treatment of limb soft tissue sarcoma should require the first resection to be thorough without tumor residue. According to past experience, repeated surgeries can lead to increased malignancy of the disease, resulting in shorter and shorter recurrence period, especially for retroperitoneal liposarcoma. However, for the prognosis of limb reoperation treatment, a large sample study by Fiore et al. found that limb sarcoma could still have a low recurrence rate and good survival rate with negative margins after reexcision despite irregular surgery, suggesting that the standardization and thoroughness of reoperation is an important issue, and the prognosis will be obviously poor if there is still tumor residue after reoperation. V. For soft tissue tumors, surgery still emphasizes the standardization and thoroughness, and stresses the importance of the first treatment. At present, patients with soft tissue tumors are admitted to orthopedics, surgical oncology, and general surgery, and there is no uniform understanding of the biological behavior of soft tissue tumors, which leads to the arbitrariness of diagnosis and treatment by clinicians, and sometimes they rush to surgery only based on local ultrasound, not to mention the preoperative histopathological diagnosis. Once malignant tumors are diagnosed after surgery, there are the same problems of whether to extend the resection, whether to treat with radiotherapy or chemotherapy, and whether different pathologists have different diagnoses. Soft tissue tumors require active participation of bone and soft tissue oncologists in the development of diagnostic and therapeutic protocols, which can further guide clinical work by summarizing clinical cases from various centers, providing evidence of evidence-based medicine, and formulating consensus and guidelines.